Pharma Supply Chains Call For Better Visibility

By David Jensen

The pandemic has managed to single-handedly undermine many critical aspects of pharmaceutical product development. Many of the manufacturing companies that had to shut down production have been slow to get back up to speed due to being understaffed from quarantined employees. In vicious-cycle fashion, supplies of raw materials needed to manufacture treatments for COVID-19 have been depleted with very few or no supplies available to restock the shelves.

Lately, it seems the only other term uttered as often as COVID-19 is supply chain. In addition to the pandemic-induced supply chain woes, global supply chains are largely becoming more complex, difficult to manage, and vulnerable to uncertainties and risks. We outline recommendations for improving your pharma supply chain operations.